Basecamp Research raises $140 million for AI-designed therapeutics

Basecamp Research announced a $140 million Series C led by S32. It plans to train a new generation of its EDEN biological models and move an AI-designed therapeutics pipeline toward clinical development, starting with an in vivo cell-therapy approach that seeks to reprogram cells inside the body. The company also plans to expand pharmaceutical partnerships.

Basecamp described the round as oversubscribed. Participants included Menlo Ventures’ Anthology Fund, Catalio Capital Management, NATO Innovation Fund, Nvidia, The Rockefeller Foundation and True Ventures, among others. The company did not disclose its valuation, financing terms, individual investor contributions, a budget allocation or a timetable for deploying the proceeds.

Basecamp describes EDEN as a biological foundation model that can design long, complex DNA sequences. Its proposed in vivo cell-therapy method pairs those designs with large serine recombinases intended to integrate the sequences into a genome. The approach differs from life-science infrastructure focused on tenant isolation for AI-generated scientific code. Basecamp’s description sets out the intended mechanics and aims, not reported clinical results.

The company said it has produced strong preclinical results across multiple modalities and disease areas. But the financing materials do not provide study designs, datasets, animal results, candidate-level findings or patient outcomes supporting that broad claim. Nor do they identify a lead therapeutic candidate, first indication, trial registration or first-in-human date.

Andy Conrad, an S32 general partner and former Verily chief executive, is joining Basecamp’s board in connection with the financing.